CN
Antibacterial in vitro screening and pharmacology services

In Vitro Platform

  • MIC screening
  • MBC, standard and simplified (coupled with MIC)
  • Serum and BPP shift assay
  • Profiling of antibacterial lead compounds
  • Time-kill curve and post-antibiotic effect
  • Synergy/potentiation assay
  • Frequency of resistance
  • Isolation of spontaneous resistant mutant
  • Drug-induced resistant mutation, isolation & characterization
  • Whole-genome sequencing & mapping of mutations
  • PCR sequencing of target genes
  • Reconstruction of resistant mutations
  • Enzymatic assays
  • Macromolecular labeling
  • Anaerobic bacteria; surrogate mycobacterium spp. for TB

 

In Vivo Platform (pharmacology, pathology and efficacy studies)

  • Superficial skin infection, localized deep-thigh infection, systemic infection and peritonitis infection
  • Pulmonary infection: Pseudomonas aeruginosa and Klebsiella pneumoniae
  • Peritonitis infection: Escherichia coli and Streptococcus pneumoniae
  • Gastrointestinal infection: Clostridium difficile
  • Systemic infection: Streptococcus suis
  • Helicobacter pylori: persistent upper gastrointestinal infection in mice and Mongolian gerbil
  • Mycobacterium tuberculosis (subcontracted)
  • In vivo antibiotic resistant study, isolation & characterization of resistant mutants

 

Integrated Services

  • Lead development and optimization: medicinal chemistry, microbiology and biochemistry, SAR study, MOA & MOR study, counter screening (cytotoxicity, hERG, CYP, transporters etc), ADME/PK study, in vivo efficacy/PD study, toxicology study; safety assessment,
  • IND package and filing